Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist

被引:371
作者
Buckley, Stephen T. [1 ]
Baekdal, Tine A. [2 ]
Vegge, Andreas [1 ]
Maarbjerg, Stine J. [2 ]
Pyke, Charles [1 ]
Ahnfelt-Ronne, Jonas [1 ]
Madsen, Kim G. [1 ]
Scheele, Susanne G. [1 ]
Alanentalo, Tomas [1 ]
Kirk, Rikke K. [1 ]
Pedersen, Betty L. [1 ]
Skyggebjerg, Rikke B. [1 ]
Benie, Andrew J. [1 ]
Strauss, Holger M. [1 ]
Wahlund, Per-Olof [1 ]
Bjerregaard, Simon [1 ]
Farkas, Erzsebet [3 ]
Fekete, Csaba [3 ,4 ]
Sondergaard, Flemming L. [2 ]
Borregaard, Jeanett [2 ]
Hartoft-Nielsen, Marie-Louise [2 ]
Knudsen, Lotte Bjerre [1 ]
机构
[1] Novo Nord AS, DK-2760 Malov, Denmark
[2] Novo Nord AS, DK-2860 Soborg, Denmark
[3] Hungarian Acad Sci, Inst Expt Med, Dept Endocrine Neurobiol, H-1083 Budapest, Hungary
[4] Tufts Med Ctr, Tupper Res Inst, Dept Med, Div Endocrinol Diabet & Metab, Boston, MA 02111 USA
关键词
INTESTINAL PERMEATION ENHANCERS; GASTRIC-MUCOSA; ORAL DELIVERY; GLYCEMIC CONTROL; LIRAGLUTIDE; FORMULATION; SODIUM; IMPACT; ACID; DRUG;
D O I
10.1126/scitranslmed.aar7047
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Oral administration of therapeutic peptides is hindered by poor absorption across the gastrointestinal barrier and extensive degradation by proteolytic enzymes. Here, we investigated the absorption of orally delivered semaglutide, a glucagon-like peptide-1 analog, coformulated with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl) aminocaprylate] (SNAC) in a tablet. In contrast to intestinal absorption usually seen with small molecules, clinical and preclinical dog studies revealed that absorption of semaglutide takes place in the stomach, is confined to an area in close proximity to the tablet surface, and requires coformulation with SNAC. SNAC protects against enzymatic degradation via local buffering actions and only transiently enhances absorption. The mechanism of absorption is shown to be compound specific, transcellular, and without any evidence of effect on tight junctions. These data have implications for understanding how highly efficacious and specific therapeutic peptides could be transformed from injectable to tablet-based oral therapies.
引用
收藏
页数:13
相关论文
共 50 条
[31]   Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes [J].
Rizzo, Manfredi ;
Rizvi, Ali A. ;
Sesti, Giorgio .
DIABETES OBESITY & METABOLISM, 2017, 19 (05) :613-614
[32]   Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism [J].
Lutz, Thomas A. ;
Osto, Elena .
CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (03) :257-263
[33]   Addition of glucagon-like peptide-1 receptor agonist therapy to insulin in C-peptide-positive patients with type 1 diabetes [J].
Kuhadiya, Nitesh D. ;
Prohaska, Ben ;
Ghanim, Husam ;
Dandona, Paresh .
DIABETES OBESITY & METABOLISM, 2019, 21 (04) :1054-1057
[34]   The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes [J].
Ho-Sang Moon ;
Mi-Kyung Kim ;
Moon-Ho Son .
Archives of Pharmacal Research, 2011, 34 :1041-1043
[35]   Potential kidney protective effects of glucagon-like peptide-1 receptor agonists [J].
Trevella, Philippa ;
Ekinci, Elif I. ;
Macisaac, Richard J. .
NEPHROLOGY, 2024, 29 (08) :457-469
[36]   The effects of glucagon-like peptide-1 on the beta cell [J].
Vilsboll, T. .
DIABETES OBESITY & METABOLISM, 2009, 11 :11-18
[37]   Impact of glucagon-like peptide-1 on endothelial function [J].
Sjoholm, A. .
DIABETES OBESITY & METABOLISM, 2009, 11 :19-25
[38]   Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice [J].
Ellenbroek, J. H. ;
Tons, H. A. M. ;
van Meeteren, M. J. A. Westerouen ;
de Graaf, N. ;
Hanegraaf, M. A. ;
Rabelink, T. J. ;
Carlotti, F. ;
de Koning, E. J. P. .
DIABETOLOGIA, 2013, 56 (09) :1980-1986
[39]   Long-acting glucagon-like peptide-1 receptor agonist-status December 2018 [J].
Holst, Jens Juul .
ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (05)
[40]   Design of Glucagon-Like Peptide-1 Receptor Agonist for Diabetes Mellitus from Traditional Chinese Medicine [J].
Tang, Hsin-Chieh ;
Chen, Calvin Yu-Chian .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 2014